Compare HAFC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFC | NGNE |
|---|---|---|
| Founded | 1982 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 915.9M | 744.9M |
| IPO Year | 2000 | 2014 |
| Metric | HAFC | NGNE |
|---|---|---|
| Price | $32.66 | $25.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $35.75 | ★ $77.88 |
| AVG Volume (30 Days) | 188.0K | ★ 342.8K |
| Earning Date | 10-27-2026 | 11-20-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | ★ 22.44 | 0.93 |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $270,165,000.00 | N/A |
| Revenue This Year | $10.28 | N/A |
| Revenue Next Year | $5.06 | N/A |
| P/E Ratio | $21.88 | ★ N/A |
| Revenue Growth | ★ 15.28 | N/A |
| 52 Week Low | $24.54 | $15.93 |
| 52 Week High | $34.46 | $43.66 |
| Indicator | HAFC | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 53.16 | 47.84 |
| Support Level | $30.29 | $24.88 |
| Resistance Level | $32.99 | $28.47 |
| Average True Range (ATR) | 0.81 | 2.50 |
| MACD | 0.07 | 0.38 |
| Stochastic Oscillator | 41.82 | 35.88 |
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.